Incidence of high altitude pulmonary oedema (HAPE)‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of high altitude cerebral oedema (HACE) ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: General‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
1 finding from 1 review
Nausea · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
1 finding from 1 review
Number of vomiting episodes · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Postoperative pain intensity in the immediate postobturation period (up to 72 hours), continuous (VAS) · participants undergoing surgery with peripheral nerve block
3 findings from 1 review
no estimate extracted
5 studies · 257 participants
Very low
no estimate extracted
9 studies · 469 participants
Low
no estimate extracted
3 studies · 296 participants
Low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · participants undergoing surgery with peripheral nerve block
3 findings from 1 review
no estimate extracted
3 studies · 172 participants
Low
no estimate extracted
3 studies · 162 participants
Low
no estimate extracted
5 studies · 257 participants
Low
Duration of sensory block (we included all studies describing duration of sensory block regardless of how it was described) · participants undergoing surgery with peripheral nerve block
1 finding from 1 review
Incidence of serious adverse events (we used the NIH definition of adverse events. A serious event includes death, a life‐threatening event that requires hospitalization or prolonged hospitalization, disability or congenital anomaly) · participants undergoing surgery with peripheral nerve block
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes any known death after randomisation (fetal, neonatal, child, child… compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes respiratory distress syndrome compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes intraventricular haemorrhage compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes necrotising enterocolitis compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review